XML 16 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Operating activities    
Net loss $ (214,794) $ (141,395)
Adjustments to reconcile net loss to net cash used in operating activities:    
Amortization of debt discount and deferred financing 7,179 1,744
Depreciation 2,486 2,336
Stock-based compensation 17,067 13,087
Charges to research expense for stock issued in asset acquisition   4,607
Restructuring charges   69
Loss on impairment 465,427  
(Gain)/ Loss on disposal of asset (8) 17
Change in fair value of derivative liability (265) 324
Non-cash changes in the fair value of contingent consideration payable (238,622) 9,228
Foreign currency remeasurement (gain)/ loss (4,932) 2,207
Non-cash deferred taxes and other tax benefits (164,585) (706)
Changes in operating assets and liabilities:    
Accounts receivable (4,288) (863)
Inventories (3,386) (3,505)
Prepaid expenses and other current assets (3,358) (2,803)
Other non-current assets (713) (660)
Account payable and accrued expenses 13,037 (2,920)
Non-current liabilities 637 684
Deferred reimbursements (12,600)  
Net cash used in operating activities (141,718) (118,549)
Investing activities    
Sale and redemption of marketable securities 230,981 165,495
Purchases of marketable securities (450,358) (199,829)
Purchases of property and equipment (3,398) (5,520)
Net cash used in investing activities (222,775) (39,854)
Financing activities    
Proceeds from issuance of common stock, net of issuance costs 243,036 97,068
Proceeds from unsecured loan agreement   30,000
Payment of capital leases (212) (118)
Payment of contingent consideration (10,000) (5,000)
Purchase of vested restricted stock units (1,067) (1,010)
Proceeds from exercise of stock options 8,841 1,456
Payment of deferred financing fees (28)  
Net cash provided by financing activities 240,570 122,396
Effect of exchange rate changes on cash and cash equivalents 1,030 (363)
Net decrease in cash and cash equivalents (122,893) (36,370)
Cash and cash equivalents at beginning of year/ period 187,026 69,485
Cash and cash equivalents at end of year/period 64,133 33,115
Supplemental disclosures of cash flow information    
Cash paid during the period for interest $ 3,662 284
Contingent consideration resolution in shares   6,115
Capital expenditures funded by capital lease borrowings   $ 850